CL Rathi, MD of Advanced Enzyme Technologies sees huge future for the company in nutrition growth along with animal nutrition.
CL Rathi, Managing Director and Chief Executive of Advanced Enzyme, said the acquisition will be EPS-accretive for FY17 and is likely to have a positive impact for FY18.
Do not need any money for capex over next two-three years, says CL Rathi, MD of Advanced Enzyme Technologies.
Speaking to CNBC-TV18, CL Rathi, MD of Advanced Enzymes (AETL) said its misguiding to compare its business with Novozymes. While AETL gets 75 percent of its business from nutrition segment, Novozymes has higher exposure to industrials where input costs are causing pressures.
Copyright © e-Eighteen.com Ltd All rights resderved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of moneycontrol.com is prohibited.